Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cycloserine for Naloxone-Precipitated Opiate Withdrawal
NCT00000194Phase 2Withdrawn
- Sponsor
- Yale University
- Start
- Jan 1993
- Primary completion
- Jan 1998
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of d-cycloserine in opioid use disorder (OUD), sponsored by Yale University. Primary endpoints: Behavioral, subjective, measures of naloxone-precipitated withdrawal and Physiological, neuroendocrine measures of naloxone-precipitated withdrawal. Planned start Jan 1993; status: withdrawn.
02
Drugs
d-cycloserine
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT00000194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00000194.